The Peptide Gold Rush Is Coming
An FDA advisory committee has recommended allowing compounding pharmacies to produce the peptide BPC-157, despite concerns over safety data and regulatory oversight. This move could signal a shift toward mainstream availability for substances previously sold on the gray market.
Why it matters
The decision highlights the tension between the growing demand for wellness-focused peptides and the FDA's mandate to ensure drug safety and efficacy.
Popular gray-market drugs may soon be easy to get through mainstream channels.
Illustration by The Atlantic. Source: Getty. July 24, 2026, 11:19 AM ET Share Save BPC-157 is rumored to heal almost anything: a sore shoulder, a bum knee, a pulled hamstring, ulcerative colitis. Maybe even traumatic brain injuries and multiple sclerosis, too. The drug—part of a class called peptides—has been around for decades. But it has recently experienced a surge in popularity, thanks in part to great peptide publicity from influencers, podcasters, and Robert F. Kennedy Jr., the secretary of health and human services. Thousands of Americans are taking it. And almost all of them are sourcing it from sketchy online vendors, many of which are supplied by manufacturers in China.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in